-

01:56:42 AM

ZLAB Stock News

ZLAB - Zai Lab Limited

10/28/20 7:30 AM

Nasdaq : ZLAB

conferences

Zai Lab Announces Upcoming Presentations in November Investor Conferences

Zai Lab Limited (“Zai Lab”) (NASDAQ: ZLAB; HKEX: 9688), an innovative commercial stage biopharmaceutical company, today announced that management from Zai Lab will present at the following upcoming virtual investor conferences in

RHEA-AI

neutral

10/09/20 8:48 AM

Nasdaq : ZLAB

Zai Lab Announces Full Exercise of the Over-allotment Option

Zai Lab Limited (NASDAQ: ZLAB; HKEX: 9688), an innovative commercial stage biopharmaceutical company, announced full exercise of the over-allotment option. We refer to the Prospectus, the allotment results announcement of the Company

RHEA-AI

very positive

10/06/20 7:30 AM

Nasdaq : ZLAB

clinical trial

Zai Lab Announces First Patient Dosed in Greater China in the Global Phase 2/3 MAHOGANY Study of Margetuximab in Gastric and Gastroesophageal Junction Cancer

Zai Lab Limited (NASDAQ: ZLAB; HKEX: 9688), an innovative commercial stage biopharmaceutical company, announced dosing of the first patient in Greater China in the global MAHOGANY study evaluating margetuximab, an investigational,

RHEA-AI

neutral

10/05/20 7:30 AM

Nasdaq : ZLAB

clinical trial

Zai Lab Announces First Patient Dosed in China in a Global Phase 3 Study of Retifanlimab in Patients with NSCLC

Zai Lab Limited (NASDAQ: ZLAB; HKEX: 9688), an innovative commercial stage biopharmaceutical company, announced dosing of the first patient in China in the global Phase 3 POD1UM-304 study evaluating retifanlimab, an investigational

RHEA-AI

neutral

09/28/20 7:30 AM

Nasdaq : ZLAB

Zai Lab Announces Closing of Hong Kong Secondary Listing

Zai Lab Limited (“Zai Lab” or the “Company”) (NASDAQ: ZLAB), an innovative commercial stage biopharmaceutical company, today announced listing of its ordinary shares on the Main Board of The Stock Exchange of Hong Kong Limited (the

RHEA-AI

neutral

09/28/20 7:30 AM

Nasdaq : ZLAB

Zai Lab Announces Closing of Hong Kong Secondary Listing

Zai Lab Limited (“Zai Lab” or the “Company”) (NASDAQ: ZLAB), an innovative commercial stage biopharmaceutical company, today announced listing of its ordinary shares on the Main Board of The Stock Exchange of Hong Kong Limited (the

RHEA-AI

neutral

09/27/20 11:21 PM

Nasdaq : ZLAB

Qiming's Portfolio Company Zai Lab Lists on Main Board of HKEX

Qiming's portfolio company Zai Lab (SEHK:9688, NASDAQ:ZLAB), an innovative commercial-stage biopharmaceutical company, officially listed on the Main Board of The Stock Exchange of Hong Kong Limited today.In this secondary listing, the issue price is HK$562

RHEA-AI

very positive

09/22/20 7:53 AM

Nasdaq : ZLAB

Zai Lab Announces Pricing of Hong Kong Secondary Listing

Zai Lab Limited (“Zai Lab” or the “Company”) (NASDAQ: ZLAB), an innovative commercial stage biopharmaceutical company, today announced the pricing of the Hong Kong secondary listing (the “Hong Kong Secondary Listing”) of 10,564,050

RHEA-AI

positive

09/19/20 7:30 AM

Nasdaq : ZLAB

clinical trial

Phase 3 NORA data of ZEJULA® (niraparib) demonstrate significant PFS benefit, regardless of biomarker status, with an improved safety profile when given with individualized starting dose regimen in Chinese women with platinum-sensitive recurrent ovarian ca

The NORA study, presented as a late-breaker oral presentation at the European Society for Medical Oncology (ESMO) 2020 Virtual Congress , demonstrates that niraparib maintenance treatment resulted in a 68 % reduction in the risk of disease progression or death in the overall study population when

RHEA-AI

neutral

09/19/20 7:30 AM

Nasdaq : ZLAB

clinical trial

Phase 3 NORA data of ZEJULA® (niraparib) demonstrate significant PFS benefit, regardless of biomarker status, with an improved safety profile when given with individualized starting dose regimen in Chinese women with platinum-sensitive recurrent ovarian ca

The NORA study, presented as a late-breaker oral presentation at the European Society for Medical Oncology (ESMO) 2020 Virtual Congress , demonstrates that niraparib maintenance treatment resulted in a 68 % reduction in the risk of disease progression or death in the overall study population when

RHEA-AI

neutral

Prev 4 5 6 7 8 9 10 11 Next

ZLAB Data

IndustryPharmaceutical Preparation Manufacturing
Websitewww.zailaboratory.com
Security nameZai Lab Limited - ADR
Issue typead
SectorManufacturing
Sic code2834
Employees2022
Tags
- Health Technology
- Biotechnology
- Manufacturing
- Pharmaceutical Preparation Manufacturing
AddressPudong
StateShanghai
CityShanghai
Zip201210
CountryChina (Mainland)

About Zai Lab Limited

Zai Lab ) is an innovative commercial stage biopharmaceutical company focused on bringing transformative medicines for cancer, infectious and autoimmune diseases to patients in China and around the world. To quickly target the large, fast-growing segments of China's pharmaceutical market and address unmet medical needs, Zai Lab's experienced team has secured partnerships with leading global biopharma companies, generating a broad pipeline of innovative drug candidates. Zai Lab has also built an in-house team with strong drug discovery and translational research capabilities, aiming to establish a global pipeline of proprietary drug candidates against targets in itsfocus areas. Zai Lab's vision is to become a fully integrated biopharmaceutical company, discovering, developing, manufacturing and commercializing its portfolio in order to impact human health worldwide.